208 related articles for article (PubMed ID: 31727009)
1. Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
Calapre L; Warburton L; Millward M; Gray ES
BMC Cancer; 2019 Nov; 19(1):1109. PubMed ID: 31727009
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
[TBL] [Abstract][Full Text] [Related]
3. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
Marsavela G; Lee J; Calapre L; Wong SQ; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Abed A; Khattak MA; Meniawy TM; Dawson SJ; Sandhu S; Carlino MS; Menzies AM; Scolyer RA; Long GV; Amanuel B; Millward M; Ziman MR; Rizos H; Gray ES
Clin Cancer Res; 2020 Nov; 26(22):5926-5933. PubMed ID: 33067256
[TBL] [Abstract][Full Text] [Related]
6. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
8. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
9. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
10. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract][Full Text] [Related]
12. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
16. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
18. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
